Summary of Study ST001474

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000993. The data can be accessed directly via it's Project DOI: 10.21228/M8BH7T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001474
Study TitleMetabolomics of lung injury after allogeneic hematopoietic cell transplantation - Spleen ICMS
Study Typepreliminary data
Study SummaryAllogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option for a variety of hematological malignancies. Interactions between the donor immune system and the patient tissue result in a disease, called GVHD. The pathophysiology of acute GVHD can be hypothesized in three sequential phases: cytokine storm and activation of the antigen-presenting cells (APC), donor T cell activation and effector cell phase. Idiopathic pneumonia syndrome (IPS) is one of the most deleterious complications after allogeneic HCT and is considered not only to be related to conditioning regimen toxicity but also represents an end organ damage caused by allo-reactive T cells, therefore making the lung susceptible to a two-pronged attack, one of which overlaps with GVHD causing other target organ injury. IPS results in mortality of up to 90% of patients. We will use a murine model of IPS and GVHD which is well established in our group, and in which disease evolves either across disparities in major histocompatibility complex (MCH) class I and II, minor histocompatibility antigens (miHags) or both. Metabolomics changes following syngeneic and allogeneic HCT at post-transplantation Days +7 (cytokine storm phase) and Days +42 (cellular effector phase) are compared to baseline wild-type (naive) controls. Prior to analysis, naïve - and experimental mice (N=3 from each group) were fed with semi-liquid diet supplemented with tracers (13C6-glucose ) over 24 hours. At the end of 7 days or 42 days, respectively, feces and aGVHD target organs (colon, liver and lung) were collected from all groups and further processed and / or analyzed. We expect to reveal metabolic pathways affected after allo-HCT which contribute to immune cell mediated lung injury (IPS) and will potentially identify different metabolic pathways in other GVHD target organs.
Institute
University of Kentucky
DepartmentMCC
Last NameHildebrandt
First NameGerhard
AddressCTW-453, 900 South Limestone street. UKY. Lexington, Kentucky-40536
Emailgerhard.hildebrandt@uky.edu
Phone800-333-8874
Submit Date2020-08-22
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2020-09-10
Release Version1
Gerhard Hildebrandt Gerhard Hildebrandt
https://dx.doi.org/10.21228/M8BH7T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Protocol
SA12456815_C1-20_Spleen_allogenic_7days_170427_UKy_GCH_rep3-polar-ICMS_Aallogenic
SA12456914_C1-2_Spleen_allogenic_7days_170427_UKy_GCH_rep2-polar-ICMS_Aallogenic
SA12457007_C1-1_Spleen_allogenic_42days_170427_UKy_GCH_rep1-polar-ICMS_Aallogenic
SA12457109_C2-0_Spleen_allogenic_42days_170427_UKy_GCH_rep1-polar-ICMS_Aallogenic
SA12457213_C1-1_Spleen_allogenic_7days_170427_UKy_GCH_rep1-polar-ICMS_Aallogenic
SA12457308_C1-2_Spleen_allogenic_42days_170427_UKy_GCH_rep2-polar-ICMS_Aallogenic
SA12457402_A1_Spleen_naive_0days_170427_UKy_GCH_rep2-polar-ICMS_Anaive
SA12457503_A2_Spleen_naive_0days_170427_UKy_GCH_rep3-polar-ICMS_Anaive
SA12457601_A0_Spleen_naive_0days_170427_UKy_GCH_rep1-polar-ICMS_Anaive
SA12457711_B1-1_Spleen_syngenic_7days_170427_UKy_GCH_rep2-polar-ICMS_Asyngenic
SA12457804_B0_Spleen_syngenic_42days_170427_UKy_GCH_rep1-polar-ICMS_Asyngenic
SA12457905_B1_Spleen_syngenic_42days_170427_UKy_GCH_rep2-polar-ICMS_Asyngenic
SA12458006_B2_Spleen_syngenic_42days_170427_UKy_GCH_rep3-polar-ICMS_Asyngenic
SA12458110_B1-0_Spleen_syngenic_7days_170427_UKy_GCH_rep1-polar-ICMS_Asyngenic
SA12458212_B1-2_Spleen_syngenic_7days_170427_UKy_GCH_rep3-polar-ICMS_Asyngenic
Showing results 1 to 15 of 15
  logo